 BofA Securities assumed coverage on shares of Coherus Biosciences NASDAQ:CHRS in a report issued on Thursday morning, Briefing.com Automated Import reports. The brokerage issued a neutral rating and a 20.00 target price on the biotechnology companys stock. Several other equities research analysts have also recently issued reports on CHRS. SunTrust Banks started coverage on Coherus ... 